Liver transplantation in HIV-HCV coinfected patients: A case-control study

Lluis Castells, Alfredo Escartín, Itxarone Bilbao, Oscar Len, Helena Allende, Víctor Vargas, Esteban Ribera, José Luis Lázaro, Javier Bueno, Joaquin Balsells, Rafael Esteban, Albert Pahissa, Carlos Margarit

Research output: Contribution to journalArticleResearchpeer-review

38 Citations (Scopus)


Liver transplantation (LT) for hepatitis C virus (HCV)-associated cirrhosis in human immunodeficiency virus (HIV)-infected patients was compared with non-HIV patients. Nine patients with HIV-HCV coinfection were compared with patients transplanted before and after each HIV patient (control group). Immunosuppression consisted in tacrolimus with steroids or mycophenolate mofetil. Acute cellular rejection and three-year actuarial patient survival were respectively 44% and 87.5% in HIV group and 22% and 93.7% in the control group (P=NS). Acute hepatitis C virus occurred earlier (2.3 vs. 4.3 months) and was more cholestatic (mean bilirubin: 10.8 vs. 1.6 mg/dL) in the HIV group. Eight (100%) HIV and nine (64.3%) control patients received antiviral treatment with pegylated interferon and ribavirin. One patient (11.1%) of the control group and one patient (20%) of the HIV group presented a sustained virologic response (P=NS). Short- to midterm results of LT in HIV-HCV co-infected patients were excellent and similar to non-HIV patients. Copyright © 2007 by Lippincott Williams & Wilkins.
Original languageEnglish
Pages (from-to)354-358
Publication statusPublished - 1 Feb 2007


  • Antiviral treatment
  • HAART toxicity
  • HCV infection
  • HCV recurrence
  • HIV infection
  • Liver transplantation


Dive into the research topics of 'Liver transplantation in HIV-HCV coinfected patients: A case-control study'. Together they form a unique fingerprint.

Cite this